Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Rocket Pharmaceuticals's RPA-601?
RPA-601 is a gene therapy commercialized by Rocket Pharmaceuticals, with a leading Phase I program in Cardiomyopathy. According to Globaldata,...
Data Insights
RPA-601 by Rocket Pharmaceuticals for Cardiomyopathy: Likelihood of Approval
RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy. According to GlobalData, Phase I...